Modus Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.83M Buy
4,162
+791
+23% +$802K 1.05% 39
2025
Q4
$3.62M Buy
3,371
+1,419
+73% +$1.36M 0.96% 39
2025
Q3
$1.49M Buy
1,952
+640
+49% +$476K 0.41% 65
2025
Q2
$1.02M Buy
1,312
+233
+22% +$181K 0.3% 67
2025
Q1
$891K Buy
1,079
+279
+35% +$232K 0.29% 68
2024
Q4
$618K Buy
800
+321
+67% +$266K 0.19% 79
2024
Q3
$424K Buy
479
+117
+32% +$105K 0.14% 93
2024
Q2
$328K Buy
362
+18
+5% +$14.4K 0.12% 93
2024
Q1
$268K Buy
+344
New +$245K 0.1% 96

Other funds holding LLY

Modus Advisors's LLY Position: Q1 2026 in Review

Modus Advisors increased its Eli Lilly (LLY) stake by 23% in Q1 2026, buying an estimated $802K and bringing the position to 4,162 shares worth $3.83M. The position accounts for 1.05% of the portfolio, ranked #39.

Modus Advisors first reported a position in LLY in Q1 2024 and has held it in 9 quarters since. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Modus Advisors held 4,162 shares of Eli Lilly worth $3.83M as of Q1 2026.
  • Modus Advisors bought 791 Eli Lilly shares in Q1 2026, an estimated $802K.
  • Eli Lilly made up 1.05% of Modus Advisors's portfolio in Q1 2026, its #39 holding.
  • Modus Advisors first reported a position in Eli Lilly in Q1 2024 and has held it in 9 quarters since.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Modus Advisors's 13F filing for Q1 2026, filed 4 May 2026.